RenovoRx (RenovoRx) Insider Ownership : 2.00 % (As of Jun. 20, 2024)

View and export this data going back to 2021. Start your Free Trial

What is RenovoRx Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, RenovoRx's insider ownership is 2.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, RenovoRx's Institutional Ownership is 0.62%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, RenovoRx's Float Percentage Of Total Shares Outstanding is 98.11%.

RenovoRx Insider Ownership Historical Data

The historical data trend for RenovoRx's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovoRx Insider Ownership Chart

RenovoRx Historical Data

The historical data trend for RenovoRx can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Insider Ownership	11.94	11.94	11.95	11.95	11.95	2.85	2.85	2.85	2.00	2.00

RenovoRx Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

RenovoRx (RenovoRx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovoRx Inc (NAS:RNXT) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

4546 El Camino Real, Suite B1, Los Altos, CA, USA, 94022

Website

https://www.renovorx.com

RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 pancreatic cancer clinical trial for its lead product candidate RenovoGem.

Executives

Angela Nelms	officer: Chief Operating Officer	C/O RENOVORX, INC., 4546 EL CAMINO REAL, SUITE B1, LOS ALTOS CA 94022
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
James M Ahlers	officer: Chief Financial Officer	2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Ramtin Agah	director, officer: Chief Medical Officer	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Shaun Bagai	director, officer: Chief Executive Officer	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Bank Of The West	10 percent owner	PO BOX 60078, LOS ANGELES CA 90060
Una S Ryan	director	329 HAMMOND STREET, CHESTNUT HILL MA 02467
David Diamond	director	29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Laurence Marton	director	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kirsten Angela Macfarlane	director	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Christopher John Lehman	officer: Chief Financial Officer	65 OAK RIDGE ROAD, BERKELEY, BERKELEY CA 94705
Paul Manners	officer: Chief Financial Officer	4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kamran Najmabadi	10 percent owner	3114 DAVID AVE., PALO ALTO CA 94303
Najmabadi Family Trust Dated April 22, 2021	10 percent owner	3114 DAVID AVE., PALO ALTO CA 94303